本报讯(记者陈潇)近日，半岛大超炮、半岛逆时针这两款刚斩获NMPAⅢ类医疗器械注册证的重磅产品 同台亮相头部能量源医美器械企业深圳半岛医疗集团股份有限公司(以下简称"半岛医疗")2026新品发布 会北京站。 据悉，半岛大超炮与半岛逆时针，分别锁定深层支撑与浅层修护，通过医工结合的高精尖技术，实现了 从筋膜层到表皮层的全方位贯通。据悉，半岛医疗旗下产品如今远销全球70多个国家和地区、覆盖国内 外上万家医院与医美机构。 半岛医疗创始人、董事长雷晓兵表示："我们的初心朴素而坚定，就是让中国上千家医院，都能买得 起、用得起曾被国际巨头垄断的尖端医疗设备。" 这份坚守的核心，源于半岛独有的"医工结合"模式。近400人的研发团队，构建起一座连接一线临床需 求与工程技术的"桥梁"——既能精准捕捉到临床一线医生和患者的痛点诉求，又能快速将需求转化为可 落地的技术方案。 中国整形美容协会会长张斌在致辞中表示："一个行业，如果不去抓创新、搞科研，是没有希望的。半 岛在超声、激光、微针领域花大量时间持续搞创新，走科研创新这条路，走对了。尽管可能很困难，但 这条路终是宽广的。" 据悉，半岛医疗在2018年调整了研发方向：必须攻克"疗 ...

中国经济网北京1月8日讯（记者 李方） 1月7日，半岛大超炮、半岛逆时针这两款刚获得NMPA III类医 疗器械注册证的产品亮相半岛医疗2026新品发布会北京站。与此同时，半岛产品已获得美国FDA、欧盟 CE等多项认证，跻身全球主流医美市场。源自中国临床医生的实战洞察、凝聚中国工程师智慧的技术 方案，正从"跟跑"转向"并跑"，开始参与塑造全球医美器械的竞争格局。 北京医院整形外科主任、教授赵红艺指出，作为风险管理等级最高的"三类有源医疗器械"，半岛逆时针 射频皮肤治疗仪获取械三认证，是其安全性与有效性的最高标准确认。其针对面部萎缩性痤疮瘢痕的多 中心临床研究数据显示，术后三个月瘢痕改善有效率达96%，受试者满意度高达97.5%。 第三方市场研究机构沙利文的数据显示，中国已成为全球增长最快的光电抗衰市场，其中超声与射频微 针两大赛道合计占比超60%，成为行业核心增长引擎。 "相信未来，中国的医美器械企业与服务机构必将走向世界，成为全球级的品牌。我们坚定看好中国医 美行业，期待中国品牌，世界共享。"雷晓兵说。 据介绍，半岛大超炮将高分辨率智能超声影像系统与治疗流程深度融合，推出SOP 3.0精准治疗体系， 构建起 ...

文/陈岩鹏 2025年底，北京的一场医疗创新大会上，一个看似不起眼的"小瓶子"成了焦点。 它里面装的是"无DMSO造血干细胞冻存保护液"。在细胞治疗领域，这几乎是一场技术伦理的双重突 破。传统冻存液因含有DMSO（二甲基亚砜）和动物血清，回输人体后常引起恶心、过敏甚至肾功能损 伤，且存在病原体污染风险。 而眼前这个由中国医学科学院血液病医院、海尔生物等团队共同研发的新产品，不仅在临床上提升了安 全性，还在一项动物实验中，将免疫缺陷小鼠的存活率得到大幅提升。 "这不是一个孤立的成果。"海尔集团董事局副主席、执行副总裁，盈康一生董事长，海医汇理事长谭丽 霞说，"它的背后，是一张正在被编织起来的网。" 这张"网"，名为"海医汇"。 "小瓶子"背后 细胞治疗被誉为医学的"第三次革命"，但一个核心瓶颈长期存在：如何让活的"细胞药物"在体外安全、 有效地保存？ 传统方法就像用"有毒的冰柜"储存食物——虽然能冻住，但解冻后可能已变质甚至带毒。患者回输后， 轻则不适，重则危及生命。 "我们临床医生最痛心的，不是技术不前沿，而是前沿技术卡在最后一个看似简单的环节上。"一位长期 从事干细胞移植的医生坦言。 海尔生物天津研发中心生 ...

2025首届医工结合创新大会11月30在北京举行，会议由中国指挥与控制学会（CICC）主办，CICC 医工结合专业委员会等单位联合承办。大会以"医工源头创新，智创健康未来"为主题，不仅汇聚众医工 结合领域的知名专家分享前沿成果，更以"医工结合开放空间・源头创新对接沙龙"打破传统学术会议范 式，推动医工融合从"观点交流"向"行动落地"。 作为2025首届医工结合创新大会的重要配套环节，"医工结合开放空间·源头创新对接沙龙"以"自组 织、去中心化、需求导向"为核心模式，打破传统会议"专家主讲、听众被动参与"的局限。来自临床机 构、工科院校、医疗企业的代表围绕智能医疗装备、AI药物研发、康复器械创新等方向自主提出议 题，现场组队展开针对性讨论，实时对接医疗场景、核心技术、产业资源。有效打通"临床需求提出、 工科技术响应、产业资源落地"的闭环，为医工结合从"学术探讨"转向"源头性突破"提供了精准对接载 体，也为后续专项合作推进奠定基础。沙龙最终促成38项实质性合作意向。 此次大会作为首届医工结合创新盛会，不仅凝聚了"医工融合是健康中国必由之路"的行业共识，更 明确了"临床需求牵引、中医药差异化突破、机制人才保障"的实 ...

2024年底，国务院办公厅发布《关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意 见》，提出到2027年，建成与医药创新和产业发展相适应的监管体系；到2035年，基本实现监管现代 化。 随后，各地陆续发布相关具体执行措施。北京近日发布的《若干措施》，从临床研发和注册上市、成果 落地和推广应用、生态集聚和链群发展、数字赋能和智慧升级、开放合作和出海远航五大维度提出具体 措施，促进行业发展。 多项举措备受关注。比如，在注册上市方面，对临床急需的创新医疗器械即收即检，无源医疗器械和诊 断试剂检验时限缩减至平均60个工作日，有源医疗器械检验时限缩减至平均90个工作日。在数字赋能方 面，支持医疗器械企业联合大模型企业开发部署行业大模型，鼓励医疗机构参考已有人工智能医疗服务 价格项目将新型人工智能辅助诊疗技术纳入使用。 近日，北京市经济和信息化局等六部门联合印发《北京市促进医疗器械产业高质量发展若干措施》（简 称《若干措施》），从五大维度推出15条具体措施，以推进医疗器械产业创新发展和提质升级，打造具 有国际影响力的高端创新医疗器械产业高地。 无独有偶，上海市人民政府办公厅也在同一时间印发《上海市全面深化药品医 ...

Core Insights - The "14th Five-Year Plan" period has seen significant achievements in the coordinated development of the Beijing-Tianjin-Hebei region, particularly in economic collaboration, innovation cooperation, and shared benefits for the populace [1] Group 1: Cultural Industry Development - The establishment of the Beijing-Tianjin-Hebei Shared Cultural Industry Port in Xianghe has attracted 78 businesses, 95% of which have relocated from Beijing, injecting new vitality into local cultural industry development [5][6] - The port features a diverse range of book categories and has become a hub for both online and offline sales, with daily shipments reaching nearly one million books nationwide [5][6] - The integration of e-commerce and traditional book sales is evident, with 13 e-commerce companies already operating within the port, achieving an average of 4,000 daily sales [6] Group 2: Technological Innovation in Food Industry - The introduction of an automated tofu bottle-filling robot by Tangshan Siwei Intelligent Technology Co., Ltd. can fill 4,800 pieces of tofu per hour, equivalent to the work of 2 skilled workers, addressing labor inefficiencies in traditional methods [8][9] - This robot represents a successful collaboration between Beijing's creative resources and Tangshan's manufacturing capabilities, with the project already securing multiple patents and setting a benchmark in the industry [9] Group 3: Medical Technology Advancements - BMC Ruimait Medical Technology Co., Ltd. has successfully developed high-performance turbine fans for home ventilators, breaking international technology monopolies and filling domestic gaps [10][11] - The company emphasizes the importance of "medical-engineering integration" to better align local medical practices with product development, addressing urgent clinical needs [11] Group 4: Agricultural Innovation - The collaboration between Zhangjiakou and Beijing has led to the development of high-quality quinoa varieties, significantly increasing yields and promoting sustainable agricultural practices [12][13] - The establishment of joint breeding research bases has facilitated the introduction of advanced breeding technologies, enhancing the local agricultural output and market reach [12][13] Group 5: Technology Transfer and Industrialization - Hebei province has focused on attracting high-quality technology transfer from Beijing and Tianjin, with a reported 2,659 billion yuan in technology contracts from 2021 to 2024, reflecting an annual growth rate of 45.5% [14][15] - The establishment of 15 pilot platforms for technology trials has enabled over 100 projects to transition from laboratory results to market-ready products, fostering the growth of technology-based enterprises [15]

Group 1 - The Guangdong-Hong Kong-Macao Greater Bay Area is forming a collaborative innovation network, with Hong Kong's science park generating cutting-edge technologies, Shenzhen rapidly converting research results into market products, Dongguan efficiently assembling precision components, and Guangzhou's logistics network distributing innovative products globally [1][2] - The "Guangdong-Hong Kong-Shenzhen" innovation cluster has topped the global innovation cluster ranking for the first time, marking a historic leap from second to first place after five consecutive years [1][2] - The collaboration in the Greater Bay Area is characterized by breaking regional barriers and integrating innovation resources, leading to the rapid growth of startups and research teams [1][2] Group 2 - The innovation collaboration in the Greater Bay Area is fundamentally a precise division of labor and resource integration among cities, creating a closed-loop system covering "R&D—transformation—manufacturing—sales" [2][3] - Hong Kong focuses on basic research, Shenzhen drives product transformation, Dongguan empowers mass production, and cities like Guangzhou provide logistics and policy support, enhancing the international competitiveness of products [2][3] - The cost advantages and complete supply chain in the Greater Bay Area attract startups, enabling them to quickly expand overseas and meet international market requirements [3][4] Group 3 - The Greater Bay Area has established an efficient bridge for transforming research results into market applications through deep collaboration between medical and engineering fields, as well as policy support and talent advantages [4][5] - The collaboration between universities and enterprises in the region exemplifies the synergy of industry-academia-research cooperation, facilitating the transformation of innovative technologies into practical applications [5][6] - The internationalization of the Greater Bay Area enhances its role as a crucial hub for linking global resources, with Hong Kong acting as a bridge for mainland innovations to enter international markets [6][7] Group 4 - The Greater Bay Area's collaborative innovation is expected to continue strengthening, enhancing the complementarity between Hong Kong's international innovation center and the mainland's industrial advantages [6][7] - The region is poised to become a global leader in scientific and technological innovation, fostering the growth of startups and accelerating the emergence of innovative results [7]

文章来源： 嘉思特医疗 转载要求：可以直接转载，请在文首注明来源 嘉思特医疗磐石自加压3D分区骨小梁生物型膝关节假体凭借四大创新设计，开启膝关节表面生物固定新时 代： 创新点一： 自加压机械稳定技术 ： 提供主动机械锁定，实现超越传统压配的即刻稳定(微动<100um)，为骨整 合奠定基础。 2025年11月14日12时28分， 国家重点小巨人企业嘉思特医疗器材（天津）股份有限公司 获批的 国家创新医疗 器械 产品"磐石自加压3D分区骨小梁生物型膝关节假体"在 天津 国家会展中心举办的第17届COA学术大会荣耀 上市！ 行业21位头部专家亲临现场，共同启动新品上市发布仪式，他们分别是： 西安交通大学第二附属医院 王坤 正教授 ， 天津医院 马信龙教授 ， 新疆医科大学第一附属医院 曹力教授 ， 浙江大学医学院附属第一医院 胡懿郃教授 ， 福建医科大学附属第一医院 张文明教授 ， 四川大学华西医院 周宗科教授 ， 重庆医科大学 附属第一医院 黄伟教授 ， 北京大学第三医院 田华教授 ， 浙江大学医学院附属第二医院 严世贵教授 ，哈 尔滨医科大学附属第二医院 吕松岑教授 ，辽宁省人民医院 白希壮教授 ，中国医科大学 ...

Core Insights - The collaboration between the Luohu District Government and Shenzhen University of Technology aims to establish the "Shenzhen University of Technology Luohu Medical Center" and "Shenzhen University of Technology Luohu Medical Industry Incubation Base" to enhance the life and health industry through innovation in systems and mechanisms [1][2] Group 1: Collaboration Details - The partnership will create a comprehensive "medical research, production, and talent" complex, promoting deep integration of industry, academia, and research [1] - The "one center, one base" initiative is located in the Health Industry Park at the Zhifeng Building in Luohu District, designed to foster an ecosystem for life and health industry services [1] Group 2: Talent and Resource Sharing - The medical center will implement a dual-hire Principal Investigator (PI) talent system to attract top scholars from Shenzhen University of Technology and clinical experts from Luohu, facilitating resource sharing [1] - The collaboration will leverage clinical resources and platform advantages to establish an innovative industry incubation space and a cell therapy drug research and transformation platform [1] Group 3: Operational Model - The incubation base will adopt a "government-led, university-driven, enterprise-operated" model, with Luohu District providing industrial space and entrusting daily operations to professional service agencies [1] - The focus will be on cutting-edge fields such as AI + medical devices, medical-engineering integration, precision medicine, and cell and gene therapy, promoting the integration of medical research and industrial transformation [1][2] Group 4: Data and Impact - Luohu District's medical institutions handle over 10 million diagnoses annually and have accumulated nearly 1000TB of medical data, providing a "technology testing ground" and opportunities for first-use by enterprises [2] - Shenzhen University of Technology, as one of the first new research-oriented universities in China, has a strong capability in scientific research innovation and talent cultivation, which will further enhance the collaborative ecosystem [2]

Core Points - The establishment of the Suzhou Integration Development Center by the Chinese Microcirculation Society aims to enhance the management of chronic diseases and promote innovation in the biomedicine industry in Suzhou [1][2] - The center will focus on technology transfer, professional talent training, and the development of technical standards in the field of chronic disease screening and prevention [1] - The collaboration between the Chinese Microcirculation Society, Suzhou Science and Technology Association, and Southeast University Suzhou Research Institute is aligned with the strategic needs of high-quality development in the biomedicine sector and the "Healthy Suzhou" initiative [1] Group 1 - The center's establishment is expected to gather top expert resources and cutting-edge technological achievements to facilitate breakthroughs in microcirculation-related disease prevention and control, high-end medical device research and development, and optimization of chronic disease management systems [1] - The center aims to significantly enhance the demonstration and leading effect of "Science and Technology Innovation China" in Suzhou [1] - Since its founding in 1993, the Chinese Microcirculation Society has been deeply involved in academic research, clinical transformation, and industry-education integration in the microcirculation field [2] Group 2 - The society has established strong academic foundations and rich expert resources in areas such as cardiovascular and cerebrovascular diseases, diabetic complications, tumor microenvironments, and tissue engineering [2] - In the current year, the society has organized over 60 experts to engage with 39 local biomedicine companies and 24 research institutions and hospitals in Suzhou, resulting in 15 cooperation intentions [2] - The society has also provided professional technical guidance to 10 local enterprises [2]